Original articles
Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
a Department of Human Anatomy, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, PR China
b Department of Clinical Laboratory, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, PR China
c Department of Oncology, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, PR China
d Department of Clinical Laboratory, People's Hospital of Yunxi County, Yunxi, PR China
Read
1606
Timeswas read the article
384
Total PDF
1222
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 8 | 9 | 17 |
| 2025 11 | 234 | 66 | 300 |
| 2025 10 | 45 | 27 | 72 |
| 2025 9 | 55 | 15 | 70 |
| 2025 8 | 46 | 12 | 58 |
| 2025 7 | 85 | 7 | 92 |
| 2025 6 | 37 | 1 | 38 |
| 2025 5 | 45 | 1 | 46 |
| 2025 4 | 57 | 2 | 59 |
| 2025 3 | 29 | 1 | 30 |
| 2025 2 | 53 | 4 | 57 |
| 2025 1 | 20 | 2 | 22 |
| 2024 12 | 27 | 3 | 30 |
| 2024 11 | 46 | 16 | 62 |
| 2024 10 | 39 | 18 | 57 |
| 2024 9 | 53 | 17 | 70 |
| 2024 8 | 41 | 19 | 60 |
| 2024 7 | 38 | 23 | 61 |
| 2024 6 | 36 | 14 | 50 |
| 2024 5 | 46 | 30 | 76 |
| 2024 4 | 45 | 19 | 64 |
| 2024 3 | 29 | 12 | 41 |
| 2024 2 | 20 | 16 | 36 |
| 2024 1 | 62 | 20 | 82 |
| 2023 12 | 26 | 30 | 56 |
Show all